NDC 54868-5684 Focalinxr
Product Information
Product Characteristics
Color(s) | BROWN (C48332) WHITE (C48325) GREEN (C48329) |
Shape | CAPSULE (C48336) |
Size(s) | 19 MM 18 MM |
Imprint(s) | NVR;D30 NVR;D10 NVR;D15 NVR;D20 |
Score | 1 |
Product Packages
NDC Code 54868-5684-0
Package Description: 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC
NDC Code 54868-5684-1
Package Description: 10 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC
This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.
Product Details
What is NDC 54868-5684?
The NDC code 54868-5684 is assigned by the FDA to the product Focalinxr which is product labeled by Physicians Total Care, Inc.. The product's dosage form is . The product is distributed in 2 packages with assigned NDC codes 54868-5684-0 30 capsule, extended release in 1 bottle, plastic , 54868-5684-1 10 capsule, extended release in 1 bottle, plastic . This page includes all the important details about this product, including active and inactive ingredients, pharmagologic classes, product uses and characteristics, UNII information and RxNorm crosswalk.
What are the uses for Focalinxr?
Focalin XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older. The effectiveness of Focalin XR in the treatment of ADHD in patients aged 6 years and older was established in two placebo-controlled studies in patients meeting DSM-IV criteria for ADHD [see Clinical Studies (14)].A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; “on the go”; excessive talking; blurting answers; can’t wait turn; intrusive. The Combined Types requires both inattentive and hyperactive-impulsive criteria to be met.Special Diagnostic ConsiderationsSpecific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of the required number of DSM-IV characteristics. Need for Comprehensive Treatment ProgramFocalin XR is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician’s assessment of the chronicity and severity of the child’s symptoms.Long-Term UseThe effectiveness of Focalin XR for long-term use, i.e., for more than 7 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use Focalin XR for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient [see Dosage and Administration (2.3)].
Which are Focalinxr UNII Codes?
The UNII codes for the active ingredients in this product are:
- DEXMETHYLPHENIDATE HYDROCHLORIDE (UNII: 1678OK0E08)
- DEXMETHYLPHENIDATE (UNII: M32RH9MFGP) (Active Moiety)
Which are Focalinxr Inactive Ingredients UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- FERRIC OXIDE YELLOW (UNII: EX438O2MRT)
- GELATIN (UNII: 2G86QN327L)
- POLYETHYLENE GLYCOL (UNII: 3WJQ0SDW1A)
- DEXTROSE (UNII: IY9XDZ35W2)
- TALC (UNII: 7SEV7J4R1U)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- TRIETHYL CITRATE (UNII: 8Z96QXD6UM)
- FD&C BLUE NO. 2 (UNII: L06K8R7DQK)
What is the NDC to RxNorm Crosswalk for Focalinxr?
RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:
- RxCUI: 899439 - dexmethylphenidate HCl 10 MG 24HR Extended Release Oral Capsule
- RxCUI: 899439 - 24 HR dexmethylphenidate hydrochloride 10 MG Extended Release Oral Capsule
- RxCUI: 899439 - dexmethylphenidate hydrochloride 10 MG 24 HR Extended Release Oral Capsule
- RxCUI: 899441 - Focalin XR 10 MG 24HR Extended Release Oral Capsule
- RxCUI: 899441 - 24 HR dexmethylphenidate hydrochloride 10 MG Extended Release Oral Capsule [Focalin]
* Please review the disclaimer below.
Product Label
We have moved the product label and warning information to a dedicated page, please follow the link below:
View Product Label